The structure of POMGNT2 provides new insights into the mechanism to determine the functional O-mannosylation site on α-dystroglycan.

core M3 fibronectin type III domain glycosyltransferase muscular dystrophy α-dystroglycanopathy

Journal

Genes to cells : devoted to molecular & cellular mechanisms
ISSN: 1365-2443
Titre abrégé: Genes Cells
Pays: England
ID NLM: 9607379

Informations de publication

Date de publication:
Jul 2021
Historique:
revised: 15 04 2021
received: 06 04 2021
accepted: 17 04 2021
pubmed: 25 4 2021
medline: 2 9 2021
entrez: 24 4 2021
Statut: ppublish

Résumé

Defects in the O-mannosyl glycan of α-dystroglycan (α-DG) are associated with α-dystroglycanopathy, a group of congenital muscular dystrophies. While α-DG has many O-mannosylation sites, only the specific positions can be modified with the functional O-mannosyl glycan, namely, core M3-type glycan. POMGNT2 is a glycosyltransferase which adds β1,4-linked GlcNAc to the O-mannose (Man) residue to acquire core M3-type glycan. Although it is assumed that POMGNT2 extends the specific O-Man residues around particular amino acid sequences, the details are not well understood. Here, we determined a series of crystal structures of POMGNT2 with and without the acceptor O-mannosyl peptides and identified the critical interactions between POMGNT2 and the acceptor peptide. POMGNT2 has an N-terminal catalytic domain and a C-terminal fibronectin type III (FnIII) domain and forms a dimer. The acceptor peptide is sandwiched between the two protomers. The catalytic domain of one protomer recognizes the O-mannosylation site (TPT motif), and the FnIII domain of the other protomer recognizes the C-terminal region of the peptide. Structure-based mutational studies confirmed that amino acid residues of the catalytic domain interacting with mannose or the TPT motif are essential for POMGNT2 enzymatic activity. In addition, the FnIII domain is also essential for the activity and it interacts with the peptide mainly by hydrophobic interaction. Our study provides the first atomic-resolution insights into specific acceptor recognition by the FnIII domain of POMGNT2. The catalytic mechanism of POMGNT2 is proposed based on the structure.

Identifiants

pubmed: 33893702
doi: 10.1111/gtc.12853
pmc: PMC8360118
doi:

Substances chimiques

Dystroglycans 146888-27-9
Glycosyltransferases EC 2.4.-
POMGNT2 protein, human EC 2.4.-
Mannose PHA4727WTP

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

485-494

Subventions

Organisme : Japan Society for the Promotion of Science
ID : JP19H05648,JP17H03987,JP16K07284
Organisme : Japan Agency for Medical Research and Development
ID : 20am0101083j0004,17gm0810010h0202,21ek0109443h0002

Informations de copyright

© 2021 The Authors. Genes to Cells published by Molecular Biology Society of Japan and John Wiley & Sons Australia, Ltd.

Références

Glycobiology. 2010 Sep;20(9):1160-9
pubmed: 20507882
Glycobiology. 2012 May;22(5):662-75
pubmed: 22241827
Structure. 1994 May 15;2(5):333-7
pubmed: 8081748
Crit Rev Biochem Mol Biol. 2015 Jul-Aug;51(4):213-27
pubmed: 27185500
Nat Commun. 2020 Jan 16;11(1):303
pubmed: 31949166
Proc Natl Acad Sci U S A. 2004 Jan 13;101(2):500-5
pubmed: 14699049
Proc Natl Acad Sci U S A. 2013 Mar 26;110(13):5004-9
pubmed: 23476064
Cell Rep. 2016 Mar 8;14(9):2209-2223
pubmed: 26923585
Biochim Biophys Acta Gen Subj. 2017 Oct;1861(10):2462-2472
pubmed: 28711406
Protein Sci. 2020 Jan;29(1):128-140
pubmed: 31606894
Glycobiology. 2015 Jul;25(7):702-13
pubmed: 25882296
Int J Mol Sci. 2020 Jan 09;21(2):
pubmed: 31936666
Genes Cells. 2021 Jul;26(7):485-494
pubmed: 33893702
Sci Rep. 2013 Nov 21;3:3288
pubmed: 24256719
Am J Hum Genet. 2012 Sep 7;91(3):541-7
pubmed: 22958903
Nature. 2011 Jan 27;469(7331):564-7
pubmed: 21240259
J Mol Biol. 2007 Sep 21;372(3):774-97
pubmed: 17681537
J Biol Chem. 2010 Aug 6;285(32):24882-91
pubmed: 20507986
Science. 2010 Jan 1;327(5961):88-92
pubmed: 20044576
J Biol Chem. 2017 Feb 10;292(6):2101-2109
pubmed: 27932460
Glycobiology. 2017 Sep 1;27(9):806-819
pubmed: 28810660
Elife. 2014 Oct 03;3:
pubmed: 25279699
Annu Rev Biochem. 2008;77:521-55
pubmed: 18518825
Glycobiology. 2006 Feb;16(2):29R-37R
pubmed: 16037492
J Biol Chem. 2016 Nov 18;291(47):24618-24627
pubmed: 27733679
Elife. 2014 Oct 03;3:
pubmed: 25279697
J Biol Chem. 2004 Jan 23;279(4):2337-40
pubmed: 14617637
Science. 2012 Jan 6;335(6064):93-6
pubmed: 22223806
Proc Jpn Acad Ser B Phys Biol Sci. 2019;95(1):39-51
pubmed: 30643095
Proc Natl Acad Sci U S A. 2011 Oct 18;108(42):17426-31
pubmed: 21987822
Science. 2013 Aug 23;341(6148):896-9
pubmed: 23929950
Dev Cell. 2001 Nov;1(5):717-24
pubmed: 11709191
Bioinformatics. 2004 May 22;20(8):1322-4
pubmed: 14871869
Glycobiology. 2014 Mar;24(3):314-24
pubmed: 24352591
J Biol Chem. 1997 Jan 24;272(4):2156-62
pubmed: 8999917

Auteurs

Rieko Imae (R)

Molecular Glycobiology, Research Team for Mechanism of Aging, Tokyo Metropolitan Geriatric Hospital and Institute of Gerontology, Itabashi-ku, Japan.

Naoyuki Kuwabara (N)

High Energy Accelerator Research Organization (KEK), Institute of Materials Structure Science, Structural Biology Research Center, Tsukuba, Japan.

Hiroshi Manya (H)

Molecular Glycobiology, Research Team for Mechanism of Aging, Tokyo Metropolitan Geriatric Hospital and Institute of Gerontology, Itabashi-ku, Japan.

Tomohiro Tanaka (T)

Laboratory of Glyco-organic Chemistry, The Noguchi Institute, Itabashi-ku, Japan.

Masato Tsuyuguchi (M)

High Energy Accelerator Research Organization (KEK), Institute of Materials Structure Science, Structural Biology Research Center, Tsukuba, Japan.

Mamoru Mizuno (M)

Laboratory of Glyco-organic Chemistry, The Noguchi Institute, Itabashi-ku, Japan.

Tamao Endo (T)

Molecular Glycobiology, Research Team for Mechanism of Aging, Tokyo Metropolitan Geriatric Hospital and Institute of Gerontology, Itabashi-ku, Japan.

Ryuichi Kato (R)

High Energy Accelerator Research Organization (KEK), Institute of Materials Structure Science, Structural Biology Research Center, Tsukuba, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH